Buerger's disease, also known as thromboangiitis obliterans, is a non-atherosclerotic, segmental inflammatory disease that most commonly affects small and medium-sized arteries and veins of the lower extremities. The exact cause of Buerger's disease is unknown, but it is strongly linked to tobacco use and smoking. The disease results in inflammation and clotting within the blood vessels, which causes them to become blocked or damaged. Common symptoms include pain, numbness, weakness, and color changes in the legs and feet due to poor blood flow. Treatment involves tobacco cessation methods, blood-thinning medications, prostanoids, and surgical therapies such as angioplasty, bypass surgery or amputation as a last resort.
The Buerger's disease market is estimated to be valued at USD 421 million in 2024 and is expected to reach USD 603 million by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
Key Takeaways
Key players operating in the Buerger's disease market are Getinge, Medtronic, Terumo Corporation, Livanova PLC, and Edwards Lifesciences Corporation. These companies are focusing on developing advanced medical devices and pharmacological treatment options to manage Buerger's disease symptoms.
The increasing prevalence of smoking globally is a major factor driving the growth of the Buerger's Disease Market. Smoking is the leading cause of Buerger's disease and initiatives to curb tobacco consumption can help control the disease. Technological advancements are being made in angioplasty devices and catheter materials to provide more effective revascularization and prevent restenosis in patients with Buerger's disease.
Market Trends
Growing research on the pathogenesis of Buerger's disease is revealing new drug targets and biomarkers that can potentially lead to the development of disease-modifying therapies. Currently available treatments only manage symptoms and focus on tobacco cessation. Personalized medicine approaches tailored to individual patient genetics and disease characteristics can potentially revolutionize Buerger's disease management. Telemedicine is gaining popularity for remote patient monitoring and follow-ups, especially important during the current pandemic. This helps reduce hospital visits and risk of infections.
Market Opportunities
The Asia Pacific region presents lucrative opportunities for players in the Buerger's disease market driven by rising healthcare spending and large patient populations. Countries with high smoking prevalence like Japan, China and India will see increased disease burden providing scope for effective screening and diagnostic tools. Combination therapies using molecular targets along with lifestyle modifications offer an opportunity to optimize treatment outcomes. Investment in developing economies can facilitate dissemination of advanced treatment technologies and serve currently underserved patient groups.
Impact of COVID-19 on Buerger's Disease market:
The COVID-19 pandemic has adversely impacted the growth of Buerger's disease market. During the initial outbreak of the pandemic in 2020, the market witnessed a decline in growth rate due to lockdowns imposed across various countries. This led to postponement of non-essential medical procedures and diagnostics for Buerger's disease. Patients suffering from the disease were also reluctant in visiting hospitals for routine check-ups due to fear of COVID infection. This reduced the demand for diagnostic tests and medication for Buerger's disease management.
However, with gradual lifting of lockdowns and increase in vaccination rates post 2021, the market is regaining its pre-pandemic growth pace. Telemedicine has emerged as a popular medium for virtual consultations and prescription of drugs for managing chronic conditions like Buerger's disease during the pandemic. Various pharmaceutical companies are also focusing on developing more effective and targeted treatment options for Buerger's disease to cater to the growing needs of patients. It is expected that with resumption of normal healthcare activities and use of telehealth, the market will witness steady growth over the forecast period.
Geographical concentration:
In terms of value, the Buerger's disease market is largely concentrated in Asia Pacific region. Countries like Japan, China and South Korea have reported higher prevalence rates of Buerger's disease owing to their rising geriatric population and increasing smoking habits among people. The APAC region accounts for over 40% share of the global market currently.
Fastest growing region:
North America region is expected to witness fastest growth in the Buerger's disease market during the forecast period. This can be attributed to growing awareness about early diagnosis and treatment of the disease, robust healthcare infrastructure and higher affordability of people in countries like U.S. and copyright. Favorable reimbursement policies are also boosting the uptake of advanced treatment options for managing peripheral arterial disease and subsequent symptoms of Buerger's disease in the region.
Get More insights on : Buerger's Disease Market
Get this Report in Japanese Language: バージャー病市場
Get this Report in Korean Language: 버거병 시장
Author Bio:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.